Strive
ASST
28.19
-1.57
-5.26%
Strive
US · ASST
#2516 by market cap
Listed 2023
28.19
-1.57
-5.26%
Live - 5344 symbols - heartbeat 296s ago
· 2026-10-08 07:00
Pre-market
27.85
-1.19%
After-hours
28.32
+0.48%
Overnight
28.03
-0.55%
- Market cap
- 2.68B
- P/E (TTM)i
- -28.19
- P/Bi
- 4.14
- EPSi
- -1.00
- Div yieldi
- 0.00%
- 52W posi
- 73%
Reader sentiment
Are you bullish or bearish on ASST?
Anonymous reader poll. Unscientific, not investment advice.
Revenue annual, last 3 years
Margins
Income statement
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 2.45M | 3.65M | -- |
| Gross profit | -10.27M | -10.35M | -- |
| Selling & admin expenses | 7.65M | 12.11M | -- |
| Research & development | -- | -- | -- |
| Operating profit | -18.02M | -22.65M | -- |
| Pretax profit | -16.91M | -21.58M | -- |
| Tax | 0 | 0 | -- |
| Net profit | -16.91M | -21.58M | -- |
| Basic EPS | -147 | -188 | -- |
| Diluted EPS | -147.10 | -187.71 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.42M | 1.51M | -- | 1.51M | 2.76M | 2.94M |
| Gross profit | -2.05M | -2.08M | -- | -27.99M | -11.72M | -14.86M |
| Selling & admin expenses | 1.97M | 1.55M | -- | 3.83M | 6.05M | 6.51M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -4.07M | -3.69M | -- | -31.90M | -17.86M | -21.46M |
| Pretax profit | -3.75M | -8.88M | -- | -393.60M | -265.91M | -257.60M |
| Tax | 0 | 0 | -- | 0 | 0 | 0 |
| Net profit | -3.75M | -8.88M | -- | -393.60M | -265.91M | -257.60M |
| Basic EPS | -33 | 0 | -- | -181 | -91 | -75 |
| Diluted EPS | -32.61 | -0.28 | -- | -180.80 | -90.60 | -75.40 |
Balance sheet
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total current assets | 16.16M | 23.76M | 71.78M |
| Cash & ST investments | 15.65M | 22.91M | 67.50M |
| Inventory | -- | -- | -- |
| Total assets | 20.19M | 28.20M | 745.53M |
| Total current liabilities | 1.52M | 3.34M | 10.78M |
| Short-term debt | 261.19K | -- | -- |
| Long-term debt | -- | -- | -- |
| Total liabilities | 4,136,412.00 | 4,855,000.00 | 14,289,000.00 |
| Total equity | 16.06M | 23.34M | 731.24M |
| Retained earnings | -27.57M | -49.15M | -474.05M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | -- | 14.69M | 114.20M | -- | 150.98M | 192.57M |
| Cash & ST investments | -- | 12.62M | 109.07M | -- | 145.60M | 188.32M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | -- | 22.43M | 792.58M | -- | 1.10B | 1.38B |
| Total current liabilities | -- | 8.02M | 9.54M | -- | 13.20M | 25.26M |
| Short-term debt | -- | 599.38K | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | 9.70M | -- |
| Total liabilities | -- | 11,714,059.00 | 13,147,000.00 | -- | 26,312,000.00 | 28,581,000.00 |
| Total equity | -- | 10.72M | 779.43M | -- | 1.07B | 1.35B |
| Retained earnings | -- | -61.77M | -268.42M | -- | -753.41M | -1.04B |
Cash flow
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -16.42M | -21.60M | -- |
| Depreciation & amortization | 98.33K | 192.00K | -- |
| Free cash flow | -17.39M | -21.62M | -- |
| Dividends paid | -- | 0 | -- |
| Stock buybacks / issuance | -- | 0 | -- |
| Ending cash balance | 2.09M | 6.16M | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -5.59M | -4.43M | -- | -24.98M | -30.99M | -8.41M |
| Depreciation & amortization | 52.00K | 54.00K | -- | 71.00K | 90.00K | 86.00K |
| Free cash flow | -5.64M | -4.50M | -- | -25.07M | -30.99M | -8.41M |
| Dividends paid | 0 | 0 | -- | -2.27M | -10.86M | -22.36M |
| Stock buybacks / issuance | 0 | 0 | -- | 545.14M | 94.95M | 211.30M |
| Ending cash balance | 8.79M | 12.62M | -- | 67.50M | 95.09M | 145.47M |
Returns & efficiency
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| ROE %i | -- | -- | -- |
| ROA %i | -83.74 | -89.19 | -- |
| ROIC %i | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- |
| EBIT margin %i | -735.67 | -620.64 | -- |
| FCF / sales %i | -- | -- | -- |
| Current ratioi | 10.66 | 7.12 | 6.66 |
| Quick ratioi | 10.33 | 6.86 | 6.26 |
| Debt / assetsi | 14.27 | 5.38 | 0.47 |
| LT debt / equityi | -- | -- | 0.60 |
| Interest coveragei | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -- | -- | -- | -- |
| ROA %i | -- | -104.95 | -- | -- | -- | -- |
| ROIC %i | -- | -- | -- | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -392.96 | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | -- | 1.83 | 11.97 | -- | 11.44 | 7.62 |
| Quick ratioi | -- | 1.62 | 11.43 | -- | 11.03 | 7.45 |
| Debt / assetsi | -- | 19.14 | 0.45 | -- | 1.19 | 0.24 |
| LT debt / equityi | -- | -- | 0.46 | -- | 1.84 | 0.51 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Asset Management is the largest reported line at 51.41% of revenue, across 3 reported segments.
- Medical Device follows at 47.19%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Asset Management51.41%
Medical Device47.19%
Corporate & Other1.39%
Quote time 2026-10-08 07:00:23 · For reference only, not investment advice and not tailored to your situation.